Efecto de Upadacitinib en la actividad de la enfermedad, el dolor, la fatiga, la función, la calidad de vida relacionada con la salud y la productividad laboral en la espondilitis anquilosante refractaria al tratamiento con fármacos biológicos
Rheumatol Ther 2023; 10:679–91 doi 10.1007/s40744-023-00536-2
Upadacitinib significantly improved patient-reported outcomes in AxSpA patients with bDMARD-IR after 14 Weeks of treatment. There were notable improvements in disease activity, pain, fatigue, function, HRQoL, and work productivity.
Navarro-Compán, et al. report results from SELECT-AXIS 2, a phase 3, randomised, double-blind, parallel-group, placebo-controlled trial. This study shows that upadacitinib is a suitable oral drug for bDMARD-IR AxSpA patients.
Keywords:
